asco.org15d
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Medscape21d
Mammalian Target of Rapamycin: Biological Function and Target for Novel Anticancer Agents
Thus far, inhibition of the mTOR pathway has focused on the use of rapamycin, along with three rapamycin analogues: temsirolimus, everolimus, and deforolimus. These agents have been studied as ...
Medscape15d
Genetic and Molecular Targets in Lymphoma
Lymphomas are a heterogeneous group of malignancies driven by different cell-cycle regulatory proteins, epigenetic modifications and aberrant signal transduction pathways. An improved ...
asco.org18d
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...